Home
HelpTEST ID PLA2M Phospholipase A2 Receptor, Monitoring, Enzyme-Linked Immunosorbent Assay, Serum
Reporting Name
PLA2R, Monitoring, ELISA, SSpecimen Type
SerumSpecimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into plastic vial
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 14 days | |
| Frozen | 14 days | ||
| Ambient | 8 hours |
Method Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | OK |
Reference Values
<14 RU/mL: Negative
14 to 19 RU/mL: Borderline
≥20 RU/mL: Positive
Day(s) Performed
Monday through Friday
Report Available
3 to 7 daysSpecimen Retention Time
7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
83520
Forms
If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.
Useful For
Distinguishing primary from secondary membranous nephropathy
Monitoring patients with membranous nephropathy, over time, for trends in anti-phospholipase A2 receptor antibody levels
Highlights
This test can be used to identify whether a specific autoantibody is present in a patient with biopsy proven membranous nephropathy or in a patient without a renal biopsy but with a clinical picture consistent with membranous nephropathy.
Anti-phospholipase A2 receptor (PLA2R) antibodies are highly specific for the diagnosis of primary membranous nephropathy.
If a patient is already known to have anti-phospholipase A2 receptor positive membranous nephropathy, this test can be used to monitor response to treatment or detect relapse.
As many as 70% to 75% of patients with primary membranous nephropathy are positive for anti-PLA2R.
A titer increase, decrease, or disappearance generally precedes a change in clinical status.